September 11, 2026 FDA Approves Isembyld as First Muscle-Targeted Treatment for Spinal Muscular Atrophy
June 15, 2026 FDA Approves Teplizumab for Children With Stage 3 Type 1 Diabetes – Despite Delays & Controversy
April 25, 2026 FDA Accelerates Psychedelic Drug Review with Priority Review Vouchers for Compass, Usona and Transcend in Mental Health Push
